Skip to main content
SpringerLink
Log in

Pharmacovigilance of Herbal Medicines: Current State and Future Directions

London, UK, 26–28 April, 2006

  • Abstracts
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

Section 1

  1. De Smet PAGM. Health risks of herbal remedies. Drug Saf 1995; 13: 81–93

    Article  PubMed  Google Scholar 

  2. De Smet PAGM. Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004; 76: 1–17

    Article  PubMed  Google Scholar 

Section 2

  1. Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies. Mutagenesis 2002; 17: 265–77

    Article  PubMed  CAS  Google Scholar 

  2. Fu PP, Xia Q, Lin G, et al. Pyrrolizidine alkaloids: genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 2004; 36: 1–55

    Article  PubMed  CAS  Google Scholar 

Section 3

  1. Rousseaux CG, Schachter H. Regulatory issues concerning the safety, efficacy and quality of herbal remedies. Birth Defects Research (Part B) 2003; 68: 505–10

    Article  CAS  Google Scholar 

  2. Marcus DM, Snodgrass WR. Do no harm: avoidance of herbal medicines during pregnancy. Obstet Gynecol 2005; 105(5 Pt 1): 1119–22

    Article  PubMed  Google Scholar 

  3. Nordeng H, Havnen GC. Use of herbal drugs in pregnancy: a survey among 400 Norwegian women. Pharmacoepidemiol Drug Saf 2004; 13(6): 371–80

    Article  PubMed  Google Scholar 

  4. Gibson PS, Prowrie R, Star J. Herbal and alternative medicine use: a cross sectional survey. Obstet Gynecol 2001; 97(4 Suppl. 1): S44

    Google Scholar 

  5. Tsui B, Dennehy CE, Tsourounis C. A survey of dietary supplement use during pregnancy at an academic medical center. Am J Obstet Gynecol 2001; 185: 433–7

    Article  PubMed  CAS  Google Scholar 

  6. Tiran D. The use of herbs by pregnant and childbearing women: a risk-benefit assessment. Complement Ther Nurs Midwifery 2003; 9(4): 176–81

    Article  PubMed  Google Scholar 

  7. Borrelli F, Capasso R, Aviello G, et al. Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstet Gynecol 2005; 105: 849–56

    Article  PubMed  Google Scholar 

Section 4

  1. Allkin R, Sampaio E. Collaboration and communication in the ‘caatinga’ of Brazil [online]. 2000. Available from URL: http://www.new-agri.co.uk/00-2/develop/dev04.html

  2. The international plant name index [online]. 2004. Available from URL: http://www.ipni.org

  3. Species [online]. 2000. Available from URL: http://www.sp2000.org

  4. Missouri Botanical Gardens. The Tropicos system [online]. Available from URL: http://mobot.mobot.org/W3T/Search/vast.html

  5. The world checklist of monocotyledons [online]. The Board of Trustees of the Royal Botanic Gardens, Kew, 2005. Available from URL: http://www.kew.org/monocotChecklist

  6. iPlants. The world’s plants online. Available from URL: http://www.iplants.org

Section 5

  1. CMPACC [online]. Available from URL: http://www.rbgkew.org.uk/scihort/ecbot/ecbot-cmpac.html

Section 6

  1. 5th International ESCOP symposium, London: Professor Ralph Edwards, WHO, 1998

Section 7

  1. European Commision. 7th Amendment to EU Cosmetics Directive [online]. 2003. Available from: URL: http://europa.eu.int/eur-lex/en/dat/2003/l_066/l_06620030311e0260035.pdf

  2. Scientific Committee on Consumer Products. Opinion on tea tree oil 2004. European Commission report SCCP/0843/04

  3. International Fragrance Association. Guidelines [online]. Available from URL: http://www.ifraorg.org/GuideLines.asp

  4. Maddocks-Jennings W. Critical incident: idiosyncratic allergic reactions to essential oils. Complement Ther Nurs Midwifery 2004; 10(1): 58–60

    Article  Google Scholar 

  5. Frosch PJ, Johansen JD, Menne T, et al. Further important sensitizers in patients sensitive to fragrances: II. Reactivity to essential oils. Contact Dermatitis 2002; 47(5): 279–87

    Article  PubMed  CAS  Google Scholar 

  6. Howie J. Developing an adverse events reporting system for skin reactions to aromatherapy: a pilot study. FACT 2004; 9Suppl. 1: 16–7

    Google Scholar 

Section 8

  1. Mahady GB. Global harmonization of herbal health claims. J Nutr 2001; 131(3s): 1120S–3S

    PubMed  CAS  Google Scholar 

  2. Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 2003; 26(12): 829–51

    Article  PubMed  Google Scholar 

  3. Hartigan-Go K. Developing a pharmacovigilance system in the Philippines, a country of diverse culture and strong traditional medicine background. Toxicology 2002; 103-7: 181–2

    Google Scholar 

Section 9

  1. Barnes J, Mills SY, Abbot NC, et al. Different standards for reporting ADR’s to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45: 496–500

    Article  PubMed  CAS  Google Scholar 

  2. Available from URL: http://www.escop.com/phytonet.htm

Section 10

  1. Fucik H, Backlund A, Farah M. Building a computerized herbal substance register for implementation and use in the WHO international drug monitoring programme. Drug Inf J 2002; 36: 839–54

    Article  Google Scholar 

  2. The Uppsala Monitoring Centre. Guidelines for herbal ATC classification. Uppsala: The UMC, 2004

Section 11

  1. Fayyad UM, Piatetsky-Shapiro G, Smyth P. From data mining to knowledge discovery: an overview. In: Fayyad UM, Piatetsky-Shapiro G, Smyth P, et al., editors. Advances in knowledge discovery and data mining. Menlo Park (CA): AAAI Press/The MIT Press, 1996: 1–34

    Google Scholar 

  2. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54(4): 315–21

    Article  PubMed  CAS  Google Scholar 

  3. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996; 46(6): 1775–6

    Article  PubMed  CAS  Google Scholar 

  4. Hauser D, Gayowski T, Singh N. Bleeding complications precipitated by unrecognized Gingko biloba use after liver transplantation. Transpl Int 2002; 15(7): 377–9

    Article  PubMed  Google Scholar 

  5. Engelberg D, McCutcheon A, Wiseman S. A case of ginseng-induced mania. J Clin Psychopharmacol 2001; 21(5): 535–7

    Article  PubMed  CAS  Google Scholar 

  6. Vazquez I, Aguera-Ortiz LF. Herbal products and serious side effects: a case of ginseng-induced manic episode. Acta Psychiatr Scand 2002; 105(1): 76–7; discussion 77-8

    PubMed  CAS  Google Scholar 

Section 12

  1. Wood L. In: Pharmacovigilance. Mann R, Andrews E, editors. John Wiley & Sons Ltd, 2002

  2. General practice research database !online]. Available from URL: http://www.GPRD.com [Accessed 2006 Jan 6]

Section 13

  1. Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 2003; 26(12): 829–51

    Article  PubMed  Google Scholar 

  2. Sinclair HK, Bond CM, Hannaford PC. Pharmacovigilance of over-thecounter products based in community pharmacy: a feasible option? Pharmacoepidemiol Drug Saf 1999; 8: 479–91

    Article  PubMed  CAS  Google Scholar 

  3. Layton D, Sinclair HK, Bond CM, et al. Pharmacovigilance of over-the-counter products based in community pharmacy: methodological issues from pilot work conducted in Hampshire and Grampian, UK. Pharmacoepidemiol Drug Saf 2002; 11: 503–13

    Article  PubMed  CAS  Google Scholar 

Section 14

  1. Reif K, Metzger W. Determination of aflatoxins in medicinal herbs and plant extracts. J Chromatogr A 1995; 692: 131–6

    Article  CAS  Google Scholar 

  2. Reif K, Schwind B. Development of high performance liquid chromatography - tandem mass spectrometry (HPLC-MS/MS) methods for the screening of mycotoxins in herbal raw materials [poster]. 51st Annual Congress of the Society for Medicinal Plant Research; 2003 Aug 31- Sep 4, Kiel

    Google Scholar 

  3. Kabelitz L. Contamination of herbal drugs in regulations and future developments. Herba Polonica 2003; 49: 89–104

    CAS  Google Scholar 

Section 15

  1. Barnes J, Aggarwal AM. Spontaneous reporting of ADRs associated with herbal medicines: a cross-sectional survey of national pharmacovigilance centres [abstract]. ISoP 2004. Drug Saf 2004; 27(12): 917

    Google Scholar 

Section 16

  1. Chrystal K, Allan S, Forgeston G, Isaacs R. The use of complementary/alternative medicine by cancer patients in a New Zealand regional treatment centre. NZ Med J 2003; 116(1168): 296–304

    Google Scholar 

  2. MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med. 2002; 35: 166–73

    Article  PubMed  Google Scholar 

  3. Grymonpre RE, McKechnie M, Briggs C. Community pharmacists’ identification of natural health product/drug interactions in older persons. Int J Pharm Prac 2003; 11: 217–23

    Article  Google Scholar 

Section 17

  1. Brooker SG, Cambie RA, Cooper R.C. New Zealand Medicinal Plants. 2nd Ed. Auckland: Heinemann; 1987

  2. Best E. Maori religion and mythology. Dominion Museum Bulletin, 1924: 10

    Google Scholar 

  3. MacDonald C. Medicines of the Maori. Auckland: Collins; 1973

    Google Scholar 

Section 18

  1. Mahady GB. Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol 2005; 4(3): 177–84

    Article  PubMed  Google Scholar 

  2. Beatty C, Denham A. Review of Practice: preliminary data collection for clinical audit. Eur J Herb Med 1998; 4(2): 32–3.

    Google Scholar 

  3. Greene JG. Constructing a standard climacteric scale. Maturitas 1998; 29: 25–31.

    Article  PubMed  CAS  Google Scholar 

Section 19

  1. MacLennan AH, Myers SP, Taylor AW. The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust 2006; 184: 27–31

    PubMed  Google Scholar 

  2. Expert committee report: Complementary medicines in the Australian health system 2003 [online]. Available from URL: http://www.tga.gov.au/docs/html/cmreport1.htm [Accessed 6 January 2006]

Section 20

  1. Mozaffarian V. A dictionary of Iranian plant names. Tehran: Farhang Moaser, 1996: 522

  2. Blumenthal M. et al. The complete German commission E monographs. 1st ed. Austin (TX): American Botanical Council, 1998: 219

    Google Scholar 

Section 21

  1. Moody JO, Hyland PJ and Bray DH. In vitro evaluation of Enantia chlorantha: constituents and derivatives for antiplasmodial and anticandidal activity. Pharm Pharmacol Lett 1995; 2: 80–2

    Google Scholar 

Section 22

  1. Carpenter L, Prazuck T, Vincent-Ballereau F, et al. Choice of traditional or modern treatment in West Burkina Fasso. World Health Forum, 1995

    Google Scholar 

  2. Sofowora A. Medicinal plants and traditional medicine in Africa. John Wiley and Sons, 1982: 198–202

    Google Scholar 

  3. Wirth DP. The significance of belief and expectancy within the spiritual healing encounter. Soc Sci Med 1995; 41(2) 249–60

    Article  PubMed  CAS  Google Scholar 

Section 23

  1. Bensky D, Clavey S, Stoger E. Chinese herbal medicine Materia Medica. 3rd ed. Seattle Eastland Press Inc, 2004

    Google Scholar 

  2. But PP-Y, Tomlinson B, Lee KL. Hepatitis related to the Chinese medicine Shou-wu-pian manufactured from Polygonum multiflorum. Vet Human Toxicol 1996; 38(4): 280–1

    CAS  Google Scholar 

  3. Panis B, Wong D, Hooymans P, et al. Recurrent toxic hepatitis in a Caucasian girl related to the use of Shou-Wu-Pian, a Chinese herbal preparation. J Pediatr Gastroenterol Nutr 2005; 41(2): 256–8

    Article  PubMed  Google Scholar 

Section 24

  1. Barnes J, Teng L, Shaw D. TCM: balancing choice and risk? Pharm J 2004; 273: 342

    Google Scholar 

  2. Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 2003; 26: 829–51

    Article  PubMed  Google Scholar 

Section 25

  1. Barnes J, Teng L, Shaw D. TCM: balancing choice and risk? Pharm J 2004; 273: 342.

    Google Scholar 

Section 26

  1. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 13(341): 387–91.

    Article  Google Scholar 

  2. Stiborova M, Fernando RC, Schmeiser HH, et al. Characterization of DNA adducts formed by aristolochic acid in target organ of rat by 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis 1994; 15: 1187–92.

    Article  PubMed  CAS  Google Scholar 

  3. Tanaka A, Nishida R, Maeda K, et al. Chinese herb nephropathy in Japan presents adult-onset Fanconi syndrome: could different components of aristolochic acid cause a different type of Chinese herb nephropathy? J Clin Nephrol 2000; 53: 301–6.

    CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pharmacovigilance of Herbal Medicines: Current State and Future Directions. Drug-Safety 29, 341–370 (2006). https://doi.org/10.2165/00002018-200629040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200629040-00005

Keywords

Search

Navigation